Publications by authors named "C C Luzzio"
Article Synopsis
- Glatiramer acetate (GA) is approved for treating relapsing multiple sclerosis, and this study examined its long-term effectiveness, particularly comparing early versus delayed treatment start.
- Participants in the trial showed that those who started GA treatment early had better outcomes, with less worsening in disability scores and longer times to disease progression than those who started treatment later.
- Overall, while GA treatment was beneficial over the long term and showed no new safety concerns, a limitation of the study was that only about 25% of participants completed the follow-up period.
Background: There have been few improvements in cerebrospinal fluid (CSF) shunt technology since John Holter introduced the silicon valve, with overdrainage remaining a major source of complications.
Objective: To better understand why valves are afflicted by supra-normal CSF flow rates. We present in Vitro benchtop analyses of flow through a differential pressure valve under simulated physiological conditions.
Intracranial Pressure Sensor and Valve to Control Hydrocephalus.
Annu Int Conf IEEE Eng Med Biol Soc
July 2018
Hydrocephalus is a neurological condition that can result from trauma, hemorrhage, cancer, and infection. To control the intracranial pressure (ICP) a shunt is implanted to drain the cerebro-spinal fluid (CSF). We are working to develop an implantable pressure sensor.
View Article and Find Full Text PDFBackground: The hygiene hypothesis suggests that microbial replacement may be therapeutic in allergic and autoimmune diseases. Nevertheless, the results of helminth treatment, including in multiple sclerosis (MS), have been inconclusive.
Objective: To assess safety and brain magnetic resonance imaging (MRI) activity in subjects with relapsing-remitting multiple sclerosis (RRMS) during oral administration of ova from the porcine whipworm, Trichuris suis (TSO).
Background: Multiple sclerosis (MS) is the most common demyelinating disease, and onset over the age of 50 years is referred to as late onset MS (LOMS). It has been thought that LOMS patients will be more likely to exhibit a primary progressive (PPMS) clinical course.
Objective: To identify the clinical characteristics of demyelinating disease in patients over the age of 50 years from four different MS centers in the Northern Midwest USA.